Navigation Links
PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
Date:7/29/2009

INCLINE VILLAGE, Nev., July 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets Healthcare Conference in New York City on Wednesday, August 5, 2009 at 3:30 p.m. Eastern Time.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site at http://www.pdl.com and click "Investors." Please connect to the Web site at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay will be available at www.pdl.com starting approximately three hours after completion of the webcast.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
2. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
5. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
6. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
7. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
8. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
9. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
10. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
11. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)...   Sienna Biopharmaceuticals, Inc. , a privately held, ... Richard Peterson will join the company as ... who brings more than two decades of global financial ... retiring at the end of April but will continue ... Sienna from Novan, Inc., where he served as Chief ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 ... "Biorefinery Products: Global Markets" report to their offering. ... The ... from $466.6 Billion in 2016 at a CAGR of 8.9%, ... of energetic and non-energetic bioproducts into seven major product segments: ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
Breaking Biology Technology:
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
Breaking Biology News(10 mins):